Head and Neck Cancer Drugs Market (By Treatment Type: Chemotherapy, Radiation Therapy, Targeted Therapy, and Immunotherapy; By Sales Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030


The global head and neck cancer drugs market size was valued at US$ 1.51 billion in 2021 and is expected to reach over US$ 2.99 billion by 2030, poised to grow at a compound annual growth rate (CAGR) of 7.9% from 2021 to 2030.

Head and Neck Cancer Drugs Market Size 2020 to 2030

Growth Factors

A number of malignant tumors that develops around throat, nose, mouth, salivary glands, and larynx. The chemotherapy in addition to other therapies are generally used for the treatment of the head and neck cancer. The rising prevalence of head and neck cancer owing to several factors such as alcohol consumption, tobacco consumption, Epstein-Barr virus (EBV) infection, and human papillomavirus (HPV) infection is significantly driving the demand for the head and neck cancer drugs. It is estimated that around 900,000 cases of neck and head cancer and around 400,000 deaths related to it are recorded annually across the globe. Moreover, males are affected as twice as the females. Therefore, these numbers are the major factors that drive the growth of the global head and neck cancer drugs market. The increasing expenditure by the top market players in the research and development and the availability of the various pipeline drugs such as Atezolizumab, Afatinib, and Ipilimumab are contributing towards the market growth.

The advancements in the non-surgical procedures and therapies such as immunotherapy and targeted therapy are supporting the adoption of the head and neck cancer drugs among the patients across the globe. The availability of advanced diagnostic tools to diagnose the various types of cancer and tumors is supplementing the market growth. The rising awareness among the population regarding the availability of effective and innovative drugs to treat cancer coupled with increasing healthcare expenditure is fueling the head and neck cancer market growth. The rapidly growing biopharmaceutical industry and the rising penetration of the online pharmacies are the major factors that are expected to augment the growth of the market during the forecast period. Moreover, the various developmental strategies such as partnerships, new product launches, and adoption of latest technologies impact the market positively and drive the market growth.

Scope of the Head and Neck Cancer Drugs Market

Report Highlights Details
Market Size by 2030 USD 2.99 Billion
Growth Rate From 2021 to 2030 7.9%
Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Treatment, Sales Channel, Region
Companies Mentioned AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Fortress Biotech, Inc, F. Hoffmann-La Roche Ltd., Immutep Limited, Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer Inc.

 

Treatment Type Insights

Based on the treatment type, the chemotherapy accounted for the largest market share in 2020. This is attributed to the increased adoption of the chemotherapy along with the radiation therapy and rise in awareness regarding the combination therapies to treat head and neck cancer. There are several drugs such as, capecitabine, cetuximab, paclitaxel, bleomycin, hydroxyurea, and docetaxel are approved for the treatment of head and neck cancer across the globe. Therefore, the rising prevalence of head and neck cancer and increased usage of chemotherapy in combination with different other therapies has fostered the growth of this segment in the past few years.

The immunotherapy is estimated to be the fastest-growing segment during the forecast period. The rising awareness among the patients regarding the effectiveness and the benefits of immunotherapy over the chemotherapy is expected to boost the growth of this segment. The growing focus of the manufacturers and the active participation of the authorities like FDA and EMA in the approval of the immunotherapy drugs is expected to augment the demand for the immunotherapy drugs for the treatment of head and neck cancer.

Sales Channel Insights

The retail pharmacies segment accounted 60% revenue share in 2020. This is attributed to the increased penetration of the retail pharmacies and various popular chains of pharmacies across the globe. Retail pharmacies are the traditional and the most popular type of sales channel among the population for buying drugs. Therefore, the increased coverage of the retail pharmacies from urban to rural areas across the globe has fostered the growth of this segment.

Head and Neck Cancer Drugs Market Share, By Sales Channel, 2020 (%)

The online pharmacies segment is expected to be the fastest-growing segment during the forecast period. The rising penetration of internet and growing adoption of smartphones are the major factors that boost the growth of the online pharmacies. According to the International Telecommunication Union, approximately 4 billion people had access to the internet in 2019 and the majority of the people were accessing to the internet using their smartphones. Furthermore, the growing popularity of the online retail platforms across the globe is driving the growth of this segment.

Region Insights

North America dominated the global head and neck cancer market in 2020. According to the American Cancer Society, head and neck cancer accounts for around 4% of the total cancer cases in US. In 2021, it is estimated that around 48,740 men and 17,890 women will develop head and neck cancer. Around 14,620 deaths are estimated to occur in US in 2021 due to head and neck cancer. Therefore, the rising prevalence of head and neck cancer is driving the growth of the head and neck cancer drugs market in North America. The presence of sophisticated healthcare infrastructure, increased healthcare expenditure, favorable reimbursement policies, enhanced access to the advanced diagnostic devices are the major factors that drives the growth of the head and neck cancer drugs market in North American region.

Asia Pacific is estimated to be the most opportunistic market during the forecast period. This can be attributed to the presence of huge population, rising prevalence of head and neck cancer owing to the rising prevalence of smoking, rising alcohol consumption, and rising tobacco consumption, rising awareness regarding the availability of innovative drugs, and rising healthcare expenditure. The rising consumer awareness towards the early diagnosis of cancer and rising demand for the advanced therapeutics is significantly fostering the market growth in this region.

Key Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.

The various developmental strategies like new product launches, acquisitions, and mergers fosters market growth and offers lucrative growth opportunities to the market players.

Some of the prominent players in the global head and neck cancer drugs market include:

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Fortress Biotech, Inc
  • F. Hoffmann-La Roche Ltd.
  • Immutep Limited
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.

Segments Covered in the Report

By Treatment Type

  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy

By Sales Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • MEA
  • Rest of the World

Frequently Asked Questions

What is the current size of head and neck cancer drugs market?
According to Precedence Research, the global head and neck cancer drugs market size was worth at US$ 1.4 billion in 2020 and is predicted to reach US$ 2.99 billion by 2030.
The global head and neck cancer drugs market is expected to drive growth at a of 7.9% from 2021 to 2030.
The rising prevalence of head and neck cancer across the globe is the primary factor behind the growth of the global head and neck cancer drugs market.
The major players operating in the head and neck cancer drugs market are AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Fortress Biotech, Inc, F. Hoffmann-La Roche Ltd., Immutep Limited, Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer Inc..
North America accounted for the largest market share of the global head and neck cancer drugs market in 2020. The enhanced access to the healthcare services and advanced diagnostic services has resulted in the early screening of the head and neck cancer in North America.
  • Report Code:1474
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Status:Published

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample